Evaluation of a New Closed-System Automated RT-qPCR Assay for the Rapid Detection and Monitoring of Common Nucleophosmin Mutations in Patients with Acute Myeloid Leukemia

Richard D. Press; Dana Dressel; Michelle McBean; Ing S. Tiong; Matthew W. Anderson; David Pride; Aarthi Raman; Rachelle R. Doom; Rajesh Kaldate

doi:10.3390/ijms25147912

Evaluation of a New Closed-System Automated RT-qPCR Assay for the Rapid Detection and Monitoring of Common Nucleophosmin Mutations in Patients with Acute Myeloid Leukemia

Richard D. Press, Dana Dressel, Michelle McBean, Ing S. Tiong, Matthew W. Anderson, David Pride, Aarthi Raman, Rachelle R. Doom, Rajesh Kaldate

Research output: Contribution to journal › Article › peer-review

Abstract

Quantitative assessment of nucleophosmin 1 (NPM1) mutation status is integral to evaluating measurable residual disease (MRD) in NPM1-mutated acute myeloid leukemia (AML) patients. In a retrospective study, leftover peripheral blood (PB) specimens (n = 40) which were collected for routine clinical diagnostic evaluations of AML disease burden were tested by both a novel automated RT-qPCR quantitative NPM1 assay (Xpert NPM1 mutation assay) and the NPM1 mutA, mutB&D MutaQuant kit. Based on a Deming regression analysis, there was a high correlation (slope = 0.92; intercept = 0.12; Pearson’s r = 0.982) between the quantitative results of the Xpert NPM1 mutation assay and the NPM1 mutA, mutB&D MutaQuant kit. The Xpert test quantitative results are thus highly correlated with the comparator method and the former has potential as a useful alternative for the monitoring of AML patients with a known NPM1 mutation.

Original language	English (US)
Article number	7912
Journal	International journal of molecular sciences
Volume	25
Issue number	14
DOIs	https://doi.org/10.3390/ijms25147912
State	Published - Jul 2024

Keywords

acute myeloid leukemia
minimal residual disease (MRD)
monitoring
nucleophosmin (NPM1) mutation
polymerase chain reaction

ASJC Scopus subject areas

Catalysis
Molecular Biology
Spectroscopy
Computer Science Applications
Physical and Theoretical Chemistry
Organic Chemistry
Inorganic Chemistry

Access to Document

10.3390/ijms25147912

Cite this

Press, R. D., Dressel, D., McBean, M., Tiong, I. S., Anderson, M. W., Pride, D., Raman, A., Doom, R. R., & Kaldate, R. (2024). Evaluation of a New Closed-System Automated RT-qPCR Assay for the Rapid Detection and Monitoring of Common Nucleophosmin Mutations in Patients with Acute Myeloid Leukemia. International journal of molecular sciences, 25(14), Article 7912. https://doi.org/10.3390/ijms25147912

Evaluation of a New Closed-System Automated RT-qPCR Assay for the Rapid Detection and Monitoring of Common Nucleophosmin Mutations in Patients with Acute Myeloid Leukemia. / Press, Richard D.; Dressel, Dana; McBean, Michelle et al.
In: International journal of molecular sciences, Vol. 25, No. 14, 7912, 07.2024.

Research output: Contribution to journal › Article › peer-review

Press, RD, Dressel, D, McBean, M, Tiong, IS, Anderson, MW, Pride, D, Raman, A, Doom, RR & Kaldate, R 2024, 'Evaluation of a New Closed-System Automated RT-qPCR Assay for the Rapid Detection and Monitoring of Common Nucleophosmin Mutations in Patients with Acute Myeloid Leukemia', International journal of molecular sciences, vol. 25, no. 14, 7912. https://doi.org/10.3390/ijms25147912

@article{b21173a9935c4b29838e306e40d2f79a,

title = "Evaluation of a New Closed-System Automated RT-qPCR Assay for the Rapid Detection and Monitoring of Common Nucleophosmin Mutations in Patients with Acute Myeloid Leukemia",

abstract = "Quantitative assessment of nucleophosmin 1 (NPM1) mutation status is integral to evaluating measurable residual disease (MRD) in NPM1-mutated acute myeloid leukemia (AML) patients. In a retrospective study, leftover peripheral blood (PB) specimens (n = 40) which were collected for routine clinical diagnostic evaluations of AML disease burden were tested by both a novel automated RT-qPCR quantitative NPM1 assay (Xpert NPM1 mutation assay) and the NPM1 mutA, mutB&D MutaQuant kit. Based on a Deming regression analysis, there was a high correlation (slope = 0.92; intercept = 0.12; Pearson{\textquoteright}s r = 0.982) between the quantitative results of the Xpert NPM1 mutation assay and the NPM1 mutA, mutB&D MutaQuant kit. The Xpert test quantitative results are thus highly correlated with the comparator method and the former has potential as a useful alternative for the monitoring of AML patients with a known NPM1 mutation.",

keywords = "acute myeloid leukemia, minimal residual disease (MRD), monitoring, nucleophosmin (NPM1) mutation, polymerase chain reaction",

author = "Press, {Richard D.} and Dana Dressel and Michelle McBean and Tiong, {Ing S.} and Anderson, {Matthew W.} and David Pride and Aarthi Raman and Doom, {Rachelle R.} and Rajesh Kaldate",

note = "Publisher Copyright: {\textcopyright} 2024 by the authors.",

year = "2024",

month = jul,

doi = "10.3390/ijms25147912",

language = "English (US)",

volume = "25",

journal = "International journal of molecular sciences",

issn = "1661-6596",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "14",

}

TY - JOUR

T1 - Evaluation of a New Closed-System Automated RT-qPCR Assay for the Rapid Detection and Monitoring of Common Nucleophosmin Mutations in Patients with Acute Myeloid Leukemia

AU - Press, Richard D.

AU - Dressel, Dana

AU - McBean, Michelle

AU - Tiong, Ing S.

AU - Anderson, Matthew W.

AU - Pride, David

AU - Raman, Aarthi

AU - Doom, Rachelle R.

AU - Kaldate, Rajesh

PY - 2024/7

Y1 - 2024/7

N2 - Quantitative assessment of nucleophosmin 1 (NPM1) mutation status is integral to evaluating measurable residual disease (MRD) in NPM1-mutated acute myeloid leukemia (AML) patients. In a retrospective study, leftover peripheral blood (PB) specimens (n = 40) which were collected for routine clinical diagnostic evaluations of AML disease burden were tested by both a novel automated RT-qPCR quantitative NPM1 assay (Xpert NPM1 mutation assay) and the NPM1 mutA, mutB&D MutaQuant kit. Based on a Deming regression analysis, there was a high correlation (slope = 0.92; intercept = 0.12; Pearson’s r = 0.982) between the quantitative results of the Xpert NPM1 mutation assay and the NPM1 mutA, mutB&D MutaQuant kit. The Xpert test quantitative results are thus highly correlated with the comparator method and the former has potential as a useful alternative for the monitoring of AML patients with a known NPM1 mutation.

AB - Quantitative assessment of nucleophosmin 1 (NPM1) mutation status is integral to evaluating measurable residual disease (MRD) in NPM1-mutated acute myeloid leukemia (AML) patients. In a retrospective study, leftover peripheral blood (PB) specimens (n = 40) which were collected for routine clinical diagnostic evaluations of AML disease burden were tested by both a novel automated RT-qPCR quantitative NPM1 assay (Xpert NPM1 mutation assay) and the NPM1 mutA, mutB&D MutaQuant kit. Based on a Deming regression analysis, there was a high correlation (slope = 0.92; intercept = 0.12; Pearson’s r = 0.982) between the quantitative results of the Xpert NPM1 mutation assay and the NPM1 mutA, mutB&D MutaQuant kit. The Xpert test quantitative results are thus highly correlated with the comparator method and the former has potential as a useful alternative for the monitoring of AML patients with a known NPM1 mutation.

KW - acute myeloid leukemia

KW - minimal residual disease (MRD)

KW - monitoring

KW - nucleophosmin (NPM1) mutation

KW - polymerase chain reaction

UR - http://www.scopus.com/inward/record.url?scp=85199862732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85199862732&partnerID=8YFLogxK

U2 - 10.3390/ijms25147912

DO - 10.3390/ijms25147912

M3 - Article

C2 - 39063154

AN - SCOPUS:85199862732

SN - 1661-6596

VL - 25

JO - International journal of molecular sciences

JF - International journal of molecular sciences

IS - 14

M1 - 7912

ER -

Evaluation of a New Closed-System Automated RT-qPCR Assay for the Rapid Detection and Monitoring of Common Nucleophosmin Mutations in Patients with Acute Myeloid Leukemia

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this